Hypogammaglobulinemia: Difference between revisions

Jump to navigation Jump to search
Line 34: Line 34:
* Between 1950-1965, primary [[immunodeficiencies]] affecting all major levels of [[immune system]] were first described.<ref name="pmid8433870">{{cite journal |vauthors=Stiehm ER |title=New and old immunodeficiencies |journal=Pediatr. Res. |volume=33 |issue=1 Suppl |pages=S2–7; discussion S7–8 |date=January 1993 |pmid=8433870 |doi=10.1203/00006450-199305001-00007 |url=}}</ref>
* Between 1950-1965, primary [[immunodeficiencies]] affecting all major levels of [[immune system]] were first described.<ref name="pmid8433870">{{cite journal |vauthors=Stiehm ER |title=New and old immunodeficiencies |journal=Pediatr. Res. |volume=33 |issue=1 Suppl |pages=S2–7; discussion S7–8 |date=January 1993 |pmid=8433870 |doi=10.1203/00006450-199305001-00007 |url=}}</ref>


* Use of immunoglobulins for the [[Treatment-resistant depression|treatmen]]<nowiki/>t of [[hypogammaglobulinemia]] was practised as early as 1950's.<ref name="pmid13357304">{{cite journal |vauthors= |title=USE OF immune globulins for the treatment of agammaglobulinemia or hypogammaglobulinemia |journal=J Am Med Assoc |volume=162 |issue=2 |pages=117 |date=September 1956 |pmid=13357304 |doi= |url=}}</ref>
* Use of [[immunoglobulins]] for the treatmen<nowiki/>t of [[hypogammaglobulinemia]] was practised as early as 1950's.<ref name="pmid13357304">{{cite journal |vauthors= |title=USE OF immune globulins for the treatment of agammaglobulinemia or hypogammaglobulinemia |journal=J Am Med Assoc |volume=162 |issue=2 |pages=117 |date=September 1956 |pmid=13357304 |doi= |url=}}</ref>
* [[Therapeutic]] results in the use of human serum [[gamma globulins]] have been published during the late 1950's. <ref name="pmid13623695">{{cite journal |vauthors=SOULIER JP, BADILLET M, HERZOG F |title=[Therapeutic results in the use of human serum gamma globulins; survey of 6, 602 cases. I. Main indications for their use in infections diseases] |language=French |journal=Presse Med |volume=66 |issue=84 |pages=1881–4 |date=November 1958 |pmid=13623695 |doi= |url=}}</ref><ref name="pmid13591696">{{cite journal |vauthors=OLIVE BADOSA A |title=[Gamma globulin in immunological therapeutics: critical analysis] |language=Spanish; Castilian |journal=Rev Clin Esp |volume=69 |issue=6 |pages=361–4 |date=June 1958 |pmid=13591696 |doi= |url=}}</ref>
* [[Therapeutic]] results in the use of human serum [[gamma globulins]] have been published during the late 1950's. <ref name="pmid13623695">{{cite journal |vauthors=SOULIER JP, BADILLET M, HERZOG F |title=[Therapeutic results in the use of human serum gamma globulins; survey of 6, 602 cases. I. Main indications for their use in infections diseases] |language=French |journal=Presse Med |volume=66 |issue=84 |pages=1881–4 |date=November 1958 |pmid=13623695 |doi= |url=}}</ref><ref name="pmid13591696">{{cite journal |vauthors=OLIVE BADOSA A |title=[Gamma globulin in immunological therapeutics: critical analysis] |language=Spanish; Castilian |journal=Rev Clin Esp |volume=69 |issue=6 |pages=361–4 |date=June 1958 |pmid=13591696 |doi= |url=}}</ref>
* [[Treatment Guidelines from The Medical Letter|Treatmen]]<nowiki/>t of various [[infectious]] [[diseases]] with the use of [[gamma globulins]] started during the late 1950's. [[Whooping cough]] was treated with [[placental]] [[immunoglobulin]] during the year 1959.<ref name="pmid13645155">{{cite journal |vauthors=LODODO KS, BAVAEVA SN |title=[Treatment of whooping cough with placental gamma-globulin] |language=Russian |journal=Pediatriia |volume=14 |issue=2 |pages=38–42 |date=February 1959 |pmid=13645155 |doi= |url=}}</ref><ref name="pmid13648484">{{cite journal |vauthors=SAXL O |title=[Treatment of severe infections with gamma globulin] |language=German |journal=Z Arztl Fortbild (Jena) |volume=52 |issue=24 |pages=1030–3 |date=December 1958 |pmid=13648484 |doi= |url=}}</ref>
* [[Treatment Guidelines from The Medical Letter|Treatmen]]<nowiki/>t of various [[infectious]] [[diseases]] with the use of [[gamma globulins]] started during the late 1950's. [[Whooping cough]] was treated with [[placental]] [[immunoglobulin]] during the year 1959.<ref name="pmid13645155">{{cite journal |vauthors=LODODO KS, BAVAEVA SN |title=[Treatment of whooping cough with placental gamma-globulin] |language=Russian |journal=Pediatriia |volume=14 |issue=2 |pages=38–42 |date=February 1959 |pmid=13645155 |doi= |url=}}</ref><ref name="pmid13648484">{{cite journal |vauthors=SAXL O |title=[Treatment of severe infections with gamma globulin] |language=German |journal=Z Arztl Fortbild (Jena) |volume=52 |issue=24 |pages=1030–3 |date=December 1958 |pmid=13648484 |doi= |url=}}</ref>

Revision as of 18:38, 6 August 2018

Hypogammaglobulinemia
ICD-10 D80.0-D80.1
ICD-9 279.00
DiseasesDB 6426
MedlinePlus 001307
eMedicine med/1120  ped/54
MeSH D000361

WikiDoc Resources for Hypogammaglobulinemia

Articles

Most recent articles on Hypogammaglobulinemia

Most cited articles on Hypogammaglobulinemia

Review articles on Hypogammaglobulinemia

Articles on Hypogammaglobulinemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hypogammaglobulinemia

Images of Hypogammaglobulinemia

Photos of Hypogammaglobulinemia

Podcasts & MP3s on Hypogammaglobulinemia

Videos on Hypogammaglobulinemia

Evidence Based Medicine

Cochrane Collaboration on Hypogammaglobulinemia

Bandolier on Hypogammaglobulinemia

TRIP on Hypogammaglobulinemia

Clinical Trials

Ongoing Trials on Hypogammaglobulinemia at Clinical Trials.gov

Trial results on Hypogammaglobulinemia

Clinical Trials on Hypogammaglobulinemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hypogammaglobulinemia

NICE Guidance on Hypogammaglobulinemia

NHS PRODIGY Guidance

FDA on Hypogammaglobulinemia

CDC on Hypogammaglobulinemia

Books

Books on Hypogammaglobulinemia

News

Hypogammaglobulinemia in the news

Be alerted to news on Hypogammaglobulinemia

News trends on Hypogammaglobulinemia

Commentary

Blogs on Hypogammaglobulinemia

Definitions

Definitions of Hypogammaglobulinemia

Patient Resources / Community

Patient resources on Hypogammaglobulinemia

Discussion groups on Hypogammaglobulinemia

Patient Handouts on Hypogammaglobulinemia

Directions to Hospitals Treating Hypogammaglobulinemia

Risk calculators and risk factors for Hypogammaglobulinemia

Healthcare Provider Resources

Symptoms of Hypogammaglobulinemia

Causes & Risk Factors for Hypogammaglobulinemia

Diagnostic studies for Hypogammaglobulinemia

Treatment of Hypogammaglobulinemia

Continuing Medical Education (CME)

CME Programs on Hypogammaglobulinemia

International

Hypogammaglobulinemia en Espanol

Hypogammaglobulinemia en Francais

Business

Hypogammaglobulinemia in the Marketplace

Patents on Hypogammaglobulinemia

Experimental / Informatics

List of terms related to Hypogammaglobulinemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Synonyms and keywords:

Overview

Hypogammaglobulinemia is a type of primary immune deficiency disease.[1]

Hypogammaglobulinemia is a characteristic of common variable immunodeficiency.[2] "Hypogammaglobulinemia" is largely synonymous with "agammaglobulinemia". When the latter term is used (as in "X-linked agammaglobulinemia") it implies that gamma globulins are not merely reduced, but completely absent. Modern assays have allowed most agammaglobulinemias to be more precisely defined as hypogammaglobulinemias,[3] but the distinction is not usually clinically relevant.

"Hypogammaglobulinemia" is distinguished from dysgammaglobulinemia, which is a reduction in some types of gamma globulins, but not others.[4]

Historical Perspective

Classification

Type OMIM Gene
AGM1 601495 IGHM
AGM2 613500 IGLL1
AGM3 613501 CD79A
AGM4 613502 BLNK
AGM5 613506 LRRC8A
AGM6 612692 CD79B

Pathophysiology

The exact pathogenesis of [disease name] is not fully understood.

OR

It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].

OR

[Pathogen name] is usually transmitted via the [transmission route] route to the human host.

OR

Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.

OR


[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].

OR

The progression to [disease name] usually involves the [molecular pathway].

OR

The pathophysiology of [disease/malignancy] depends on the histological subtype.

Causes

Hypogammaglobulinemia is caused by:

Primary or congenital B-cell disorders X-linked agammaglobulinemia, Common variable immunodeficiency, transient hypogammaglobulinemia of infancy, IgG subclass deficiency,severe combined immunodeficieny, Wiskott-Aldrich syndrome, Ataxia-telanectasia
Cardiovascular No underlying causes
Dermatologic No underlying causes
Drugs Gold, D- penicillamine, Sulfasalazine, anticonvulsants, glucocorticoids, methotrexate, calcineurin inhibitors, rituximab
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental Ionizing radiation, Toxins
Gastroenterologic protein losing enteropathy, intestinal lymphangiectasia, Cirrhosis
Hematologic Thymoma
Iatrogenic Radiation
Infectious Disease Herpes, Measles, Mycobacterial, Malaria, helminthic infections
Nutritional / Metabolic Protein energy malnutrition
Obstetric/Gynecologic Ovarian cancer
Oncologic Chronic lymphocytic leukemia, Multiple myeloma, Thymoma
Overdose / Toxicity
Pulmonary bronchiectasis
Renal / Electrolyte Nephrotic syndrome, Hemodialysis
Trauma
Urologic No underlying causes
Miscellaneous

Differentiating Hypogammaglobulinemia from Other Diseases

Hypogammaglobulinemia must be differentiated from Bronchiectasis, complement deficiencies, and cystic fibrosis

Medical condition Characteristic features
Complement deficiencies
  • Caused by a genetic defect in one of the genes that code for different complement proteins
  • Constitute about 7-9% of primary immunodeficiencies
  • Deficiency of C1q, C2, C4 tend to be linked with autoimmune diseases.
  • C5-C9 deficiency more prone to meningococcal disease.
Bronchiectasis
  • Secondary to an infectious process resulting in distortion of conducting bronchi
  • Copious mucopurulent sputum production lasting for months to years
  • Hemoptysis
  • Dyspnea, pleuritic chest pain, wheezing, fever, weight loss
Cystic fibrosis
  • Glomeruonephritis in most cases resolves after infection subsides
  • Decreased levels of C3 is transient
  • Immunoflouroescence microscopy shows immunoglobulin deposition in poststreptococcal infection
Staphylococcal associated glomerulonephritis
  • Glomerulonephritis resolves after infection subsides
  • Decreased C3 is transient
  • Immunofluorescence microscopy shows immunoglobulin deposition in staphylococcal associated glomerulonephritis.

Epidemiology and Demographics

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.

OR

In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

OR

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.


Patients of all age groups may develop [disease name].

OR

The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.

OR

[Disease name] commonly affects individuals younger than/older than [number of years] years of age.

OR

[Chronic disease name] is usually first diagnosed among [age group].

OR

[Acute disease name] commonly affects [age group].


There is no racial predilection to [disease name].

OR

[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].


[Disease name] affects men and women equally.

OR

[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


The majority of [disease name] cases are reported in [geographical region].

OR

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Risk Factors

Common risk factors in the development of hypogammaglobulinemia include:

Screening

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Natural History, Complications, and Prognosis

Common complications of hypogammaglobulinemia include:

Diagnosis

Diagnostic Study of Choice

The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].

OR

The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].

OR

The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].

OR

There are no established criteria for the diagnosis of [disease name].

History and Symptoms

The majority of patients with [disease name] are asymptomatic.

OR

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

Physical Examination

Common physical examination findings of hypogammaglobulinemia include :

Laboratory Findings

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

OR

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

OR

[Test] is usually normal among patients with [disease name].

OR

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

OR

There are no diagnostic laboratory findings associated with [disease name].

Electrocardiogram

There are no ECG findings associated with hypogammaglobulinemia.

X-ray

There are no x-ray findings associated with [disease name].

OR

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with [disease name].

OR

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

CT scan

There are no CT scan findings associated with [disease name].

OR

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

MRI

There are no MRI findings associated with [disease name].

OR

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

Other Imaging Findings

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

There are no other diagnostic studies associated with [disease name].

OR

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Surgery

Surgical intervention is not recommended for the management of [disease name].

OR

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

OR

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

OR

Surgery is the mainstay of treatment for [disease or malignancy].

Primary Prevention

There are no established measures for the primary prevention of hypogammaglobulinemia

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

References

  1. Template:DorlandsDict
  2. Template:DorlandsDict
  3. Template:DorlandsDict
  4. Template:DorlandsDict
  5. Rose DW (2007). "Robert A. Good, the March of Dimes, and immunodeficiency: an historical perspective". Immunol. Res. 38 (1–3): 51–4. PMID 17917009.
  6. Stiehm ER (January 1993). "New and old immunodeficiencies". Pediatr. Res. 33 (1 Suppl): S2–7, discussion S7–8. doi:10.1203/00006450-199305001-00007. PMID 8433870.
  7. "USE OF immune globulins for the treatment of agammaglobulinemia or hypogammaglobulinemia". J Am Med Assoc. 162 (2): 117. September 1956. PMID 13357304.
  8. SOULIER JP, BADILLET M, HERZOG F (November 1958). "[Therapeutic results in the use of human serum gamma globulins; survey of 6, 602 cases. I. Main indications for their use in infections diseases]". Presse Med (in French). 66 (84): 1881–4. PMID 13623695.
  9. OLIVE BADOSA A (June 1958). "[Gamma globulin in immunological therapeutics: critical analysis]". Rev Clin Esp (in Spanish; Castilian). 69 (6): 361–4. PMID 13591696.
  10. LODODO KS, BAVAEVA SN (February 1959). "[Treatment of whooping cough with placental gamma-globulin]". Pediatriia (in Russian). 14 (2): 38–42. PMID 13645155.
  11. SAXL O (December 1958). "[Treatment of severe infections with gamma globulin]". Z Arztl Fortbild (Jena) (in German). 52 (24): 1030–3. PMID 13648484.
  12. Christou E, Giardino G, Worth A, Ladomenou F (November 2017). "Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab". Int. Rev. Immunol. 36 (6): 352–359. doi:10.1080/08830185.2017.1346092. PMID 28800262. Vancouver style error: initials (help)
  13. Taneja A, Chhabra A. PMID 28846295. Missing or empty |title= (help)


Template:WikiDoc Sources